首页> 外文期刊>Cardiovascular & hematological agents in medicinal chemistry >Drastic reduction of piperacillin-tazobactam concentrations in an in-vitro model of continuous venovenous hemofiltration: Proposal of an innovative modality of administration to maintain them at constant concentration
【24h】

Drastic reduction of piperacillin-tazobactam concentrations in an in-vitro model of continuous venovenous hemofiltration: Proposal of an innovative modality of administration to maintain them at constant concentration

机译:在体外连续静脉血液滤过模型中大幅降低哌拉西林-他唑巴坦的浓度:一种创新的给药方式以维持其恒定浓度的提议

获取原文
获取原文并翻译 | 示例
       

摘要

Background/Aims: Critically-ill patients often undergo continuous renal replacement therapy (CRRT) and need antimicrobial therapy. Piperacillin and tazobactam (Pip-Tzb) are cleared by CRRT. Our aim is to evaluate Pip-Tzb removal in an in-vitro-single-pool-model of continuous-veno-venous-hemofiltration (CVVH); we test a new method of Pip-Tzb administration during CRRT assuring constant levels of concentrations above the minimum inhibitory concentration (MIC). Methods: In an in-vitro-single-pool-model of CVVH, two solutions (Protein-Free-Solution, PFS and Fresh-Frozen-Plasma, FFP) added with Pip-Tzb were tested for Pip-Tzb removal and adsorption. Then, to keep concentrations constantly above the MIC during CVVH, we add Pip-Tzb in the reinfusion bags. Results: Pip-Tzb rapidly decreased than the MIC during CVVH. The adsorption was irrelevant in the test with FPS. Adding Pip-Tzb in the reinfusion bags of the CVVH system, we observed constant concentrations of Pip-Tzb over time. Conclusion: The association of Pip-Tzb is rapidly cleared with a real risk of inadequate dosages in patients undergoing CRRT. Adding Pip-Tzb in the reinfusion bags above the MIC, we obtained stability of concentrations during CVVH.
机译:背景/目的:重症患者通常会接受连续的肾脏替代治疗(CRRT),并且需要抗菌治疗。通过CRRT清除哌拉西林和他唑巴坦(Pip-Tzb)。我们的目的是在连续静脉-静脉血液滤过(CVVH)的体外单池模型中评估Pip-Tzb的去除;我们在CRRT过程中测试了一种新的Pip-Tzb给药方法,以确保恒定浓度水平保持在最低抑制浓度(MIC)以上。方法:在体外单池模型中,测试了添加了Pip-Tzb的两种溶液(无蛋白溶液,PFS和Fresh-Frozen-Plasma,FFP)对Pip-Tzb的去除和吸附作用。然后,为了在CVVH期间保持浓度始终高于MIC,我们在回输袋中添加Pip-Tzb。结果:在CVVH期间,Pip-Tzb比MIC迅速降低。在FPS测试中,吸附是无关紧要的。在CVVH系统的回输袋中添加Pip-Tzb,我们观察到随时间推移Pip-Tzb的浓度恒定。结论:Pip-Tzb的相关性很快被清除,存在接受CRRT的患者出现剂量不足的真实风险。在MIC上方的回输袋中添加Pip-Tzb,我们获得了CVVH期间浓度的稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号